MGMT and neoplasm: 2022), the authors stated that “Among patients whose tumor contained a methylated MGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy; “their median survival was 21.7 months as compared with 15.3 months among those who were assigned to only radiotherapy. In the absence of methylation of the MGMT promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups”.